

28. Mitteilungsblatt

Nr. 40

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2024/2025
28. Stück; Nr. 40

Bevollmächtigungen

40. Bevollmächtigungen gem. § 27 Abs. 2 UG

40. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitel	Organisationseinheit	Projektleiter(in)
FA731B1803	“RETHINK REFLUX Registry - Research to further inform thinking about the role of LINX for Reflux Disease”	Allgemeinchirurgie_7 31	Schoppmann Sebastian
FA731B1804	Eine verblindete randomisierte Studie von RefluxStop im Vergleich zur Nissen Fundoplikatio bei der Behandlung der gastroösophagealen Refluxkrankheit (GERD)	Allgemeinchirurgie_7 31	Schoppmann Sebastian
FA731B2401	“Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial” (“Studie”).	Allgemeinchirurgie_7 31	Exner Ruth
FA731B2401	“Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial” (“Studie”).	Allgemeinchirurgie_7 31	Exner Ruth
FA731E0609	GRAFALON for Induction Therapy in Liver Transplantation (GRIL)	Allgemeinchirurgie_7 31	Berlakovich Gabriela
FA731E0610	Liver transplantation in patients with Cirrhosis and severe Acute-on-Chronic Liver Failure (ACLF): indications and outcomes (CHANCE) Study	Allgemeinchirurgie_7 31	Berlakovich Gabriela
FA731E0612	Vergleichende Single Solution Strategie mit HTK bei hypothermer Maschinenperfusion	Allgemeinchirurgie_7 31	Berlakovich Gabriela
FA731E0612	Vergleichende Single Solution Strategie mit HTK bei hypothermer Maschinenperfusion	Allgemeinchirurgie_7 31	Berlakovich Gabriela
FA731E0613	Einfluss von LCP-Tacrolimus auf das Mikrobiom nach Lebertransplantation	Allgemeinchirurgie_7 31	Berlakovich Gabriela

FA731X0201	An oncolytic influenza A virus adapted to primary organotypic cultures of a CRC patient cohort via directed evolution	Allgemeinchirurgie_731	Kabiljo Julijan
FA738A0818	ICU Data for Europe	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A1303	Klinischen Prüfung der pharmakologische Sicherheit und Wirksamkeit des Prüfpräparates AP301 powder for reconstitution for solution for inhalation in Patienten mit pulmonalem Permeabilitätsödem bei Patienten mit mäßigem bis schwerem akutem Atemnotsyndrom (ARDS)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738A1304	Prospektive, randomisierte Studie zur Personalisierten Medizin mit Pentaglobin nach einer interventionellen Fokussanierung bei Peritonitis-Patienten	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738A1309	A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738A2702	A Post-Marked Clinical Follow up Study to evaluate BD Pure Hub Disinfecting Cap use on needle-free connectors	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Windpassinger Marita
FA738A2703	An Investigational Study to evaluate the safety and performance of the BD PosiFlush™SafeScrub on needleless access devices.	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Windpassinger Marita
FA738A3101	"Performance evaluation of non-invasive continuous hemodynamic measurement from Task Force® CORE versus invasive reference	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Reiterer Christian
FA738A3102	The PROTECT 2 Study: Pressure Injury Treatment by Intermittent Electrical Stimulation: A Randomized, Controlled Trial	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Reiterer Christian
FA738A3201	A federated INfrastructure for Data of Intensive CAre uniTs in Europe	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738B0501	VER-CLBP-001	Anästhesie, Allgemeine	Sator Sabine

		Intensivmedizin und Schmerztherapie_738	
FA738C0506	Evaluation of the Eleveld Pharmacokinetic Model for Propofol and Remifentanyl in Cardiac Anesthesia with Cardiopulmonary Bypass	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Hutschala-Kinstner Doris
FA738C0702	Eine prospektive, randomisierte, doppelblinde, Placebo kontrollierte Studie zur Evaluierung von Landiololhydrochlorid in der Prävention von Vorhofflimmern bei Patienten mit Herzoperation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Steinlechner Barbara
FA738C0803	Multizentrische, doppelblinde, placebokontrollierte Phase-III-Studie zur Wirksamkeit und Sicherheit von aus Humanplasma gewonnenem Antithrombin (Atentativ) in Patienten mit Heparinresistenz, die einer Herzoperation unterzogen werden, bei der ein kardiopulmonaler Bypass erforderlich ist.	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Tschernko Edda
FA613A0504	Roles of Epitranscriptomics in Diseases "ROPES"	Anatomie und Zellbiologie_310	Jantsch Franz-Michael
FA613A1101	Dextromethorphan (DM) Abuse and Male Infertility - A Pilot Exploration into Potential Epigenetic Modulation	Anatomie und Zellbiologie_310	Arand Julia
FW613A0101	FWF Preserving Immunological Memory of Previous Generations	Anatomie und Zellbiologie_310	Schäfer Matthias
FW613A0401	Filamin RNA-editing controls cellular and organ integrity	Anatomie und Zellbiologie_310	Jantsch Franz-Michael
FW613A0402	Deciphering RNA modification patterns along single molecules	Anatomie und Zellbiologie_310	Jantsch Franz-Michael
FW613A0501	Evolution of germline immunity against transposons	Anatomie und Zellbiologie_310	Miller Wolfgang
FA746A0286	Retinomics for precision profiling of coronary heart disease risk	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0288	Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula

FA746A0289	I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0320	General Research Funding - Funding Agreement	Augenheilkunde und Optometrie_746	Pieh Stefan
FA746A0321	An Investigation of the Relevance of IOL Dislocation, Pre- and Post-operatively, in Cataract Surgery Patients: A Prospective, Open-Label Multi-Center Study	Augenheilkunde und Optometrie_746	Pieh Stefan
FA746A0802	VEREINBARUNG FÜR ALLGEMEINE UNTERSTÜTZUNG IN FORSCHUNG UND LEHRE	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A0803	A Prospective, randomized, controlled, post-marketing clinical study to assess clinical performance and safety of OPTIFLEX XTENSE CONFORT PLUS intraocular lens (IOL) versus OPTIFLEX GENESIS COMFORT NY IOL in patients with planned age-related cataract surgery	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A0804	Data Transfer Agreement: Evaluation of the Visual Outcome of a Multifocal Intraocular Lens	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A1504	The Human Foveal Connectome	Augenheilkunde und Optometrie_746	Pollreisz Andreas
FA746A1509	A Randomized, Double-Masked, Multicenter, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal Eye103 Compared with Intravitreal Ranibizumab (0.5mg) in Participants with Diabetic Macular Edema	Augenheilkunde und Optometrie_746	Pollreisz Andreas
FA746A1652	Influence of Fluid Fluctuation on the Development of Fibrosis and Atrophy in nAMD under Intravitreal Faricimab Treatment mit dem zugelassenen Arzneimittel Vabysmo® (Faricimab)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan

FA746A1655	A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+ / ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2008	A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease	Augenheilkunde und Optometrie_746	Stifter Eva
FA746A2607	A randomized, double-blind, placebo-controlled, 12-month phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treatment-naïve or untreated for at least 6 months	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A2611	A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A2613	A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A2614	A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures	Augenheilkunde und Optometrie_746	Pemp Berthold

FA746A2805	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Augenheilkunde und Optometrie_746	Dunavölgyi Roman
FA746A3109	Multicentric Clinical Study to investigate the Clinical Performance of LuxSmart Intraocular lens (IOL) in comparison to the LuxGood IOL (Clinical Study #CE2201)	Augenheilkunde und Optometrie_746	Leydolt Christina
FA746A3111	Evaluation of Visual Outcome of Vivinex Impress IOL	Augenheilkunde und Optometrie_746	Leydolt Christina
FA746A3304	A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis	Augenheilkunde und Optometrie_746	Funk Marion
FA746A3306	A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis	Augenheilkunde und Optometrie_746	Funk Marion
FA746A3701	Rotational stability and refractive outcomes of the single piece hydrophobic acrylic Clareon toric intraocular lens - IIT#69799777	Augenheilkunde und Optometrie_746	Schartmüller Daniel
FA746A3701	Rotational stability and refractive outcomes of the single piece hydrophobic acrylic Clareon toric intraocular lens - IIT#69799777	Augenheilkunde und Optometrie_746	Schartmüller Daniel
FA746A3702	Visual performance of the AcrySof Vivity hydrophobic intraocular lens (IOL) in patients with mild irregular astigmatism	Augenheilkunde und Optometrie_746	Schartmüller Daniel
FA746A3702	Visual performance of the AcrySof Vivity hydrophobic intraocular lens (IOL) in patients with mild irregular astigmatism	Augenheilkunde und Optometrie_746	Schartmüller Daniel
FA746A3901	STAR-LIFE: A POST-MARKET REGISTRY ON MINIJECT	Augenheilkunde und Optometrie_746	Kiss Barbara

FA746A4003	A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus	Augenheilkunde und Optometrie_746	Aschauer Julia
FA662A0408	Execution of scientific Studies - Temporary Cerebral & Distal body Embolic protection during Cardac procedures & Surgeries.	Biomedizinische Forschung und Translationale Chirurgie_308	Podesser Bruno Karl
FA662A0901	RNA-LPX therapy for myocardial infarction / MI Drug Candidate	Biomedizinische Forschung und Translationale Chirurgie_308	Kiss Attila
FA662A1004	Effects of TRPC6 channel activation and inhibition in blood cells on expression of TRPC6 and cell function	Biomedizinische Forschung und Translationale Chirurgie_308	Hohensinner Philipp
FA662A0406	Octapharma AG - Appendix A	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0503	"In vivo study of a compliant graft material for treatment for the treatment of aortic disease"	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0801	Funktionelle Regeneration von Meniskus mithilfe von 3D-Druck mit "Bioinks" basierend auf Seide-Menisc 3D-Seidendruck	Biomedizinische Forschung_308	Schneider Karl
FA727A0605	Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina
UE65406001	Kooperationsvertrag zwischen MedUni Wien, Core Facility Labortierzucht und -haltung und der Fachhochschule Wiener Neustadt GmbH im Bereich der nichtklinischen Forschung an der Tiereinrichtung MedAustron	Core Facility Labortierzucht und -haltung_668	Höllriegl Werner
FA722A0205	Tissue-resident memory T cells and fibroblast subsets as therapeutic targets in morphea	Dermatologie_722	Sary Georg
FA722A0206	PrEPent: A novel tool to prevent bacterial STIs	Dermatologie_722	Sary Georg
FA722A0503	Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis.	Dermatologie_722	Jonak Constanze

FA722A1701	Tracking Ewing sarcoma origin by developmental and trans-species genomics	Dermatologie_722	Farlik-Födinger Matthias
FA722A1902	ESCMID Tick saliva facilitates <i>Borrelia burgdorferi</i> transmission to human skin - a role for tolerogenic Langerhans cells	Dermatologie_722	Strobl Johanna
FA722A2301	Genetic architecture of chronic fatigue syndrome	Dermatologie_722	Wielscher Matthias
FA722B1144	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)	Dermatologie_722	Höller Christoph
FA722B2203	Psoriasis therapie-Register Graz	Dermatologie_722	Jonak Constanze
FA722B2312	Flower-Power	Dermatologie_722	Mildner Michael
FA722C0904	Unraveling the mechanisms of octenidine dihydrochloride efficacy on human skin.	Dermatologie_722	Elbe-Bürger Adelheid
FA722C1209	A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis.	Dermatologie_722	Kinaciyan Tamar
FA722C1216	A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucricitibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema	Dermatologie_722	Kinaciyan Tamar
FA722C1413	A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis.	Dermatologie_722	Bangert Christine
FA722C1415	A randomized, double-blinded, active comparator-controlled, 16-week, single-site, exploratory, mechanistic trial to assess the effect of LEO 138559 on the molecular signature and safety in adults with moderate to severe atopic dermatitis	Dermatologie_722	Bangert Christine

FA722C1416	A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis	Dermatologie_722	Bangert Christine
FW722A0501	Autonome Pigmentierung epithelialer Zellen	Dermatologie_722	Eckhart Leopold
FA603A0301	Hirnforschung an Instituten der Kaiser-Wilhelm-Gesellschaft im Kontext nationalsozialistischer Unrechtstaten: Hirnpräparate in Instituten der Max-Planck-Gesellschaft und die Identifizierung der Opfer	Ethik, Sammlungen und Geschichte der Medizin_390	Czech Herwig
FA603A0303	Hirnforschung an Instituten der Kaiser-Wilhelm-Gesellschaft im Kontext nationalsozialistischer Unrechtstaten: Abschlussphase	Ethik, Sammlungen und Geschichte der Medizin_390	Czech Herwig
FA751B0109	A multicenter, prospective, observational study to evaluate the use of the sFlt-1/PlGF ratio in the risk stratification of pregnant women with signs and symptoms of preeclampsia or diagnosed preeclampsia in current clinical practice	Frauenheilkunde_751	Zeisler Harald
FA751B0604	Der Einfluss von Probiotika auf die Insulinsensitivität bei übergewichtigen Schwangeren	Frauenheilkunde_751	Göbl Christian
FA751B0703	A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)	Frauenheilkunde_751	Farr Alex
FA751B0901	Physician-guided and app-guided remote ultrasound for fetal monitoring in low to moderate risk pregnancies using the Pulsenmore device - A feasibility randomized controlled trial	Frauenheilkunde_751	Binder Julia
FA751C0648	Real World Evidence Collection Of Effectiveness Data Of First Line Ribociclib In Combination With Endocrine Therapy In Hormone-Receptor Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (aBC) In Austria – REACH AUT	Frauenheilkunde_751	Singer Christian

FA751C0654	A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status	Frauenheilkunde_751	Singer Christian
FA751C0667	Austrian BRCA-associated metastatic breast cancer registry	Frauenheilkunde_751	Singer Christian
FA751C0684	Establishment of a blood and tissue based biobank of breast cancer patients	Frauenheilkunde_751	Singer Christian
FA751C1209	Patient Preference for the Administration of Pegfilgrastim (PFI) versus Pegfilgrastim (PFS) for the Prevention of Neutropenia in Breast Cancer Patients receiving Myelosuppressive Chemotherapy	Frauenheilkunde_751	Pfeiler Georg
FA751C1211	A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1502	"Health Database" - Study concerning of real-world (RW) treatment patterns and clinical outcomes in newly diagnosed advanced OC patients stratified by BRCA status	Frauenheilkunde_751	Grimm Christoph
FA751C1607	A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy	Frauenheilkunde_751	Concin Nicole
FA751C1610	A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line or Third-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (MK-2870-020/GOG-3101/ENGOT-Cx20)	Frauenheilkunde_751	Polterauer Stephan
FA751C1801	Die Effekte von Präbiotika bei Patientinnen mit Ovarialkarzinom unter Chemotherapie - Pilotstudie	Frauenheilkunde_751	Aust Stefanie

FA751C1901	Treatment regimens and outcomes of BC patients with BRCA gene variants – a study of the ATHENA registry	Frauenheilkunde_751	Tan Yen Yen
FA751C1902	The International BRCA 1/2 Carrier Cohort Study (IBCCS): prospective cohort analyses	Frauenheilkunde_751	Tan Yen Yen
FA751C2002	Who are the breast cancer patients meeting eligibility criteria for adjuvant CDK4/6 inhibitor treatment? A real-world retrospective data analysis?	Frauenheilkunde_751	Deutschmann Christine
FA751C2301	Etablierung einer urogynäkologischen Biobank	Frauenheilkunde_751	Palmrich Pilar
FA751C2401	Evaluating ovarian reserve after conventional laparoscopy versus robotic surgery for bilateral endometrioma: a prospective, randomized controlled trial	Frauenheilkunde_751	Bekos Christine
FA751C2501	Orale Lactobacillus-Supplementierung zur Behandlung des Syndroms der überaktiven Blase	Frauenheilkunde_751	Bodner-Adler Barbara
FA744B1204	Allergen-induced IgE production: A mechanism for progression towards severe allergy	Hals-, Nasen- und Ohrenkrankheiten_744	Eckl-Dorna Julia
FA744C0104	Biofilmbildung auf Grenz- und Oberflächen aktiver Implantate und Elektrostimulation zur Therapie von Rekurrensparesen	Hals-, Nasen- und Ohrenkrankheiten_744	Schneider-Stickler Berit
FW744B0101	Understanding mechanisms of allergic symptom loss with age	Hals-, Nasen- und Ohrenkrankheiten_744	Eckl-Dorna Julia
UE74406001	Psychoacoustic evaluation of the auditory perception in cochlear implant patients with electric as well as acoustic stimulation	Hals-, Nasen- und Ohrenkrankheiten_744	Riss Dominik
UE74406001	Psychoacoustic evaluation of the auditory perception in cochlear implant patients with electric as well as acoustic stimulation	Hals-, Nasen- und Ohrenkrankheiten_744	Riss Dominik

FA711C0960	R1979-ONC-2105: A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 × ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3)	Hämatologie und Hämostaseologie_7111	Valent Peter
FA731C1409	Educational Grant: Advanced training in surgical therapy of congenital heart valve defects	Herzchirurgie_732	Zimpfer Daniel
FA731C1410	Educational Grant - Heart Failure Personal - Anstellungskosten	Herzchirurgie_732	Zimpfer Daniel
FA731C2102	Intuity Database	Herzchirurgie_732	Coti Iuliana
FA731C2201	Preventing Oxidative stress induced Systemic Inflammation after invasive Cardiac surgery with Alkaline Phosphatase (APPIRED III)	Herzchirurgie_732	Riebandt Julia
FA731C2203	Forschungsprojekt Xenios: "Efficassy i-cor-synchronised cardiac assist"	Herzchirurgie_732	Zimpfer Daniel
FA732A0101	ARIES HM3 Antiplatelet Removal and Hemocompatlbility Events with the Heartmate 3 Pump (CRD_971 ARIES)	Herzchirurgie_732	Zimpfer Daniel
FA732A0105	Prospektives, observatives, einarmiges, multizentrisches europäisches Register von Patienten, die sich einer bioprothetischen SAVR mit der AVALUS-Klappe unterziehen	Herzchirurgie_732	Zimpfer Daniel
FA732A0402	Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0404	Ausbildungsvertrag - VAD Coordinator Course / HeartMate 3TM LVAS Training	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0411	Mechanical Characterization of the BrioVAD Left Ventricular Assist Device Driveline	Herzchirurgie_732	Schlöglhofer Thomas

FA732A0412	BiVACOR TAH – Human Factors Simulation Study	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0505	Development of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus
FA732A0510	Development of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus
FA732A0702	Nicht-ischämische Spenderherz-Präservierung in der Herztransplantation - eine randomisierte, kontrollierte, multizentrische Studie	Herzchirurgie_732	Zuckermann Andreas
FA732A0801	The One Month Dual Antiplatelet Therapy With Ticagrelor in CABG Patients (ODIN) trial	Herzchirurgie_732	Sandner Sigrid
FA732A0803	STICH3C CMR Beobachtungsstudie (STICOS): Eine Beobachtungsstudie mit Magnetresonananzuntersuchung des Herzens bei Patienten mit reduzierter Pumpfunktion	Herzchirurgie_732	Sandner Sigrid
FA732A0804	VEST RESTART - a retrospective observational study	Herzchirurgie_732	Sandner Sigrid
FW732A0101	Hemocompatibility of Rotodynamic Blood Pumps PIN5467323	Herzchirurgie_732	Granegger Marcus
UE73206003	CDG Internship 2024	Herzchirurgie_732	Granegger Marcus
UE73206003	CDG Internship 2024	Herzchirurgie_732	Granegger Marcus
FA620A0103	Prefrontal circuits for cognitive flexibility in an extradimensional set-shifting task for mice and humans	Hirnforschung_360	Klausberger Thomas
FA627A0402	4BL cells: novel mediators of tissue damage in relapsing and progressive multiple sclerosis	Hirnforschung_360	Bauer Jan
FA684A0103	Identification of readouts for the evaluation of treatment strategies in RCDP	Hirnforschung_360	Berger Johannes
FW627A0102	Molecular control of autonomic nervous system cell types	Hirnforschung_360	Adameyko Igor
FW627A0103	Brain Resilience	Hirnforschung_360	Adameyko Igor
FW627A0201	Novel pathogenic B cell subsets driving tissue damage in MS	Hirnforschung_360	Bauer Jan
FW629A0201	Neuronal circuits in health and disease	Hirnforschung_360	Harkany Tibor

FA711A0165	Randomisierte Studie zur Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp), welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten	Innere Medizin I_711	Preusser Matthias
FA711A0317	The Vitdalize Study: Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a multicenter, placebo-controlled double-blind phase III RCT	Innere Medizin I_711	Burgmann Heinz
FA711A0603	VALANX Hypersensitivity	Innere Medizin I_711	Starkl Philipp
FA711A0605	Genetic perturbation of primary mast cells	Innere Medizin I_711	Starkl Philipp
FA711B0719	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomized phase III study	Innere Medizin I_711	Preusser Matthias
FA711B0805	Real World Evidence Collection Of Effectiveness Data Of First Line Ribociclib In Combination With Endocrine Therapy In Hormone-Receptor Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (aBC) In Austria – REACH AUT (CLEE011AAT01)	Innere Medizin I_711	Preusser Matthias
FA711B0964	a phase-II, open-label, randomized, parallel arm study of NIS793 (with and without Spartalizumab) in combination with SOC chemotherapy Gemcitabine/nab-Paclitaxel, and Gemcitabine/nab-Paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) - interner Studiencode CNIS793B12201	Innere Medizin I_711	Preusser Matthias
FA711B0964	a phase-II, open-label, randomized, parallel arm study of NIS793 (with and without Spartalizumab) in combination with SOC chemotherapy Gemcitabine/nab-Paclitaxel, and Gemcitabine/nab-Paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) -	Innere Medizin I_711	Preusser Matthias

	interner Studiencode CNIS793B12201		
FA711B0983	Eine randomisierte Phase II Studie zur Zweitlinienbehandlung mit liposomalem Irinotecan und 5-FU im Vergleich zu liposomalen Irinotecan mit S1 bei Patienten mit einem metastasierten Pankreaskarzinom die eine Erstlinientherapie mit Gemcitabine erhalten haben	Innere Medizin I_711	Preusser Matthias
FA711B0993	Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY	Innere Medizin I_711	Preusser Matthias
FA711B1012	Austrian registry for evaluation of treatment patterns and outcome in patients with advanced pancreatic ductal adenocarcinoma (PDAC)	Innere Medizin I_711	Preusser Matthias
FA711B1019	Nachweise aus der klinischen Praxis zum langfristigen Überleben von Patienten mit metastasiertem duktalem Adenokarzinom des Pankreas (mPDAC) nach der Behandlung mit liposomalem Irinotecan	Innere Medizin I_711	Preusser Matthias
FA711B1035	A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy (DESTINY Breast Respond HER2-low Europe)	Innere Medizin I_711	Preusser Matthias

FA711B1036	Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma	Innere Medizin I_711	Preusser Matthias
FA711B1037	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)	Innere Medizin I_711	Preusser Matthias
FA711B1038	Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of SO95029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction/gastric cancer	Innere Medizin I_711	Preusser Matthias
FA711B1039	a phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1	Innere Medizin I_711	Preusser Matthias
FA711B1040	A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Tarlatamab Therapy in subjects with limited-stage small-cell lung cancer (LS-SCLC) who have not progressed following concurrent chemoradiation therapy	Innere Medizin I_711	Preusser Matthias

FA711B1041	A Phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy	Innere Medizin I_711	Preusser Matthias
FA711B1042	Amino acid PET for PrEdiction and monitoring of vorAsidenib Response in IDH-mutant gliomas (APPEAR)	Innere Medizin I_711	Preusser Matthias
FA711B1043	Wirksamkeit von Somatuline Autogel bei Patienten mit fortgeschrittenen gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NETs) gemäß Ki-67 Proliferationsindex: Eine Studie unter Verwendung von Real-World-Daten in Europa (KINETICS)	Innere Medizin I_711	Preusser Matthias
FA711B1044	Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) - AIO-KRK-0217	Innere Medizin I_711	Preusser Matthias
FA711B1045	Guiding Multi-Modal Therapies against minimal residual disease by liquid biopsies	Innere Medizin I_711	Preusser Matthias
FA711B1046	A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab versus Pembrolizumab in the First-Line Treatment of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Innere Medizin I_711	Preusser Matthias
FA711B1047	Services in connection with planning a phase 1 clinical trial for testing of OncoOne's antibody ON203 in patients with solid tumors	Innere Medizin I_711	Preusser Matthias
FA711C0632	JHTB-Studie - A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms	Innere Medizin I_711	Valent Peter

FA711C0902	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis	Innere Medizin I_711	Valent Peter
FA711C0903	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Innere Medizin I_711	Valent Peter
FA711C0903	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Innere Medizin I_711	Valent Peter
FA711C0953	Observation of AML CR1 maintenance therapy with particular emphasis on handling the self-injection of histamine dihydrochloride and Interleukin-2	Innere Medizin I_711	Valent Peter
FA711C0954	A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalodmide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of therapy Including an Anti-CD38 Antibody and Lenalidomide	Innere Medizin I_711	Valent Peter

FA711C0955	Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL	Innere Medizin I_711	Valent Peter
FA711C0957	A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTRAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)	Innere Medizin I_711	Valent Peter
FA711C0958	R1979-ONC-2075: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2)	Innere Medizin I_711	Valent Peter
FA711C0959	A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)	Innere Medizin I_711	Valent Peter
FA711C0961	A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF ODRONEXTAMAB (REGN1979) AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, AND CEMIPIMAB (REGN2810), AN	Innere Medizin I_711	Valent Peter

	ANTI-PROGRAMMED DEATH-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH B- CELL MALIGNANCIES (CLIO-1)		
FA711C0962	Evaluation of anti-cancer stem cell activity of different type-I interferons in myeloid neoplasms: a preclinical pilot study	Innere Medizin I_711	Valent Peter
FA711C1094	A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)	Innere Medizin I_711	Jäger Ulrich
FA711C1097	eSMART: Verlaufsuntersuchung von Lebensqualität bei Krebspatienten der Abteilung für Hämatologie mittels der psychoonkologischen Basisdiagnostik	Innere Medizin I_711	Valent Peter
FA711C1401	A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors; Protocol ID: NN7769-4514	Innere Medizin I_711	Ay Cihan
FA711C1405	Addition of factor VIIa to formula milk may improve the immature intestinal epithelial barrier of preterm newborns	Innere Medizin I_711	Ay Cihan
FA711C1411	Eine multizentrische, randomisierte, offene Phase-III-Studie, mit verblindeter Auswertung der Zielparameter, die die Wirkung von Abelacimab im Verhältnis zu Apixaban auf wiederkehrende venöse Thromboembolien (VTE) und Blutungen bei Patienten mit krebsbedingten VTE vergleicht (ASTER)	Innere Medizin I_711	Ay Cihan

FA711C1416	Takeda Educational Grant 2023 für Tätigkeiten junger Kolleg*innen und Personal im medizinischen Bereich der Hämostaseologie	Innere Medizin I_711	Ay Cihan
FA711D0315	Observational Study on the Clinical Use of EVUSHELD (AZD7442) in Austria	Innere Medizin I_711	Burgmann Heinz
FA711D0316	A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with moderate or severe COVID-19.	Innere Medizin I_711	Burgmann Heinz
FA711D0501	Establishing Galleria Mellonella culture for discovering plant-based anti-infective drugs	Innere Medizin I_711	Lell Bertrand
UE71106002	Register für Patienten mit angeborener Blutgerinnungsstörung - Österr. Hämophileregister	Innere Medizin I_711	Pabinger Ingrid
UE71106013	Spende der Amgen GmbH – Personalkostenförderung	Innere Medizin I_711	Pabinger Ingrid
FA714B0392	A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study	Innere Medizin II_714	Lang Irene
FA714B0392	A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study	Innere Medizin II_714	Lang Irene
FA714B0398	A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in newly Diagnosed Intermediate- and High risk patients	Innere Medizin II_714	Lang Irene

FA714B0399	Eine prospektive, multizentrische, internationale, nicht-interventionelle Studie zur Beobachtung langfristiger Behandlungsmuster und realer Ergebnisse bei PAH-Patienten der Gruppe I, die zuvor teilgenommen haben an der TripleTRE - TripleTRE NIS	Innere Medizin II_714	Lang Irene
FA714B0541	Porcine acute myocardial infarction model for immune cell profiling and therapy	Innere Medizin II_714	Pavone-Gyöngyösi Mariann
FA714B1712	Clinical Study Agreement - OSIRIS	Innere Medizin II_714	Gwechenberger Marianne
FA714B2807	CHIP	Innere Medizin II_714	Niessner Alexander
FA714B4706	Eine randomisierte, doppelblinde klinische Prüfung der Phase III zur Beurteilung der Wirksamkeit von Balcinrenon / Dapagliflozin im Vergleich zu Dapagliflozin auf das Risiko von Herzinsuffizienz-Ereignissen und kardiovaskulärem Tod bei Patient:innen mit Herzinsuffizienz und eingeschränkter Nierenfunktion	Innere Medizin II_714	Badr Eslam Roza
FA714B4916	Protocol 20230016 - "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)" / "Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-3-Studie zur Tarlatamab-Therapie bei Patienten mit kleinzelligem Lungenkarzinom im lokal begrenzten Stadium (LS-SCLC), die nach simultaner Chemoradiotherapie noch keine Progression haben (DeLLphi-306)	Innere Medizin II_714	Gangl Clemens
FA714B5303	Aortic Stenosis and Cardiac Amyloidosis - Insights on Current Treatment Strategies	Innere Medizin II_714	Nitsche Christian

FA714B5304	2.2Artificial Intelligence-based Detection of Early-Stage Cardiac Amyloidosis on Bone Scintigraphy	Innere Medizin II_714	Nitsche Christian
FA714B5401	COVID-19 Infektion und chronisch thromboembolische Lungenerkrankung (chronisch thromboembolische pulmonale Hypertension, CTEPH und chronisch thromboembolische Erkrankung, CTEPD) - Pilotstudie	Innere Medizin II_714	Skoro-Sajer Nika
FA714B5802	Intercepting post-BURN injury cardiac muscle wasting and HEART failure: deciphering the molecular pathomechanisms for diagnostic and therapeutic intervention development (BURNING HEART)	Innere Medizin II_714	Mayr Manuel
FA714B5901	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)	Innere Medizin II_714	Lang Irene
FA714B5902	An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)	Innere Medizin II_714	Lang Irene
FA714B5903	Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsi-on-I The SPIRARE I Study	Innere Medizin II_714	Lang Irene
FA714B6001	Effects of Mavacamten in Patients with Hypertrophic Cardiomyopathy	Innere Medizin II_714	Dalos Daniel
FA714B6101	Intrakoronare Imaging	Innere Medizin II_714	Hemetsberger Rayyan
FA714B6201	Secondary Prevention in Coronary High Risk Intervention Procedures	Innere Medizin II_714	Koller Lorenz
FA714C0607	ORION-19 + ORION-20 Zusatzvertrag - Kooperation mit Univ.-Klinik für Kinder- und Jugendheilkunde	Innere Medizin II_714	Willfort-Ehringer Andrea
FA714C0712	Bolt Lithotripsy RESTORE ATK Trial for PAD (RESTORE ATK)	Innere Medizin II_714	Schlager Oliver

FA714D0511	A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)	Innere Medizin II_714	Idzko Marco
FA714D0512	A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexamipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)	Innere Medizin II_714	Idzko Marco
FA714D0513	Eine unverblindete Verlängerungsstudie zur langfristigen Sicherheit und Wirksamkeit von oral verabreichtem BI 1015550 bei Patienten mit idiopathischer Lungenfibrose (IPF) und progredienter Lungenfibrose (PPF)	Innere Medizin II_714	Idzko Marco
FA714D0803	nCLE-guided bronchoscopy for peripheral lung cancer diagnosis; a Randomized Controlled Trial	Innere Medizin II_714	Gompelmann Daniela
FW714B0101	Insights into the renin-angiotensin system in ATTR-CM	Innere Medizin II_714	Binder-Rodriguez Christina
UE71406018	Forschungszuwendungen	Innere Medizin II_714	Hemetsberger Rayyan
UE71406020	ATTR-CM (Screening Projekt)	Innere Medizin II_714	Duca Franz
FA716B0628	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a).	Innere Medizin III_716	Kautzky-Willer Alexandra

FA716B0629	A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B1002	Eine randomisierte, doppelblinde, Placebo kontrollierte Studie zur Bewertung der Sicherheit und Wirksamkeit von Crinecerfont (NBI-74788) bei erwachsenen Patienten mit klassischem kongenitalem adrenogenitalem Syndrom, gefolgt von einer unverblindeten Behandlung	Innere Medizin III_716	Kiefer Florian
FA716B1312	Prävalenz seltener genetischer Adipositas-Erkrankungen - Mutationen bei Patienten mit bariat-rischen Operationen in jungen Jahren - eine Pilotstudie	Innere Medizin III_716	Krebs Michael
FA716B1313	A phase III, randomized, double-masked, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of Satralizumab in participants with moderate-to-severe thyroid eye disease.	Innere Medizin III_716	Krebs Michael
FA716C0829	Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome	Innere Medizin III_716	Sunder-Plaßmann Gere
FA716C0830	Morbus Fabry	Innere Medizin III_716	Sunder-Plaßmann Gere
FA716C0917	A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant	Innere Medizin III_716	Böhmig Georg

	Recipients With Antibody-Mediated Rejection		
FA716C1022	"A controlled, open-label, post authorisation efficacy and safety study in Imlifidase desensitized kidney transplant patients with positive crossmatch against a deceased donor prior to Imlifidase treatment, including non-comparative registry and concurrent reference cohorts"	Innere Medizin III_716	Oberbauer Rainer
FA716C1503	Closing the Loop in Hemodialysis: A Precision Medicine Approach	Innere Medizin III_716	Hecking Manfred
FA716C2901	A Multi-country, Multi-center, Retrospective Chart Review to Describe the Use of Maribavir and its Effectiveness in Patients with Post-Transplant Cytomegalovirus infection/disease - ARISE	Innere Medizin III_716	Eskandary Farsad
FA716C2902	Detection of Therapy-Refractory CMV Courses after Kidney Transplantation to Reduce (Subclinical) Rejections through Timely Treatment	Innere Medizin III_716	Eskandary Farsad
FA716C3001	An Observational Study on Role of Complement in Kidney Diseases or Kidney-Related Diseases	Innere Medizin III_716	Mayer Katharina
FA716D0725	„A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis“	Innere Medizin III_716	Scheinecker Clemens
FA716D0809	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1)	Innere Medizin III_716	Aletaha Daniel
FA716D0813	IMAGING FOR PATIENT BENEFIT IN ARTHRITIS	Innere Medizin III_716	Aletaha Daniel

FA716D0814	Defining Clinical and Molecular Phenotypes of Multi-Drug Resistance in difficult to treat Rheumatoid Arthritis	Innere Medizin III_716	Aletaha Daniel
FA716D1303	Publikationen der INSTITUTION	Innere Medizin III_716	Karonitsch Thomas
FA716D2002	Cell profiling of pan versus selective JAKinibs in healthy controls and RA patients	Innere Medizin III_716	Bonelli Michael
FA716D2003	Evaluation of data related to the selectivity of Elancos and other JAK inhibitors	Innere Medizin III_716	Bonelli Michael
FA716D2201	The clinical utility of IRF5 activation status in RMDs	Innere Medizin III_716	Heinz Leonhard
FA716E0867	A Phase 3 multicenter, open-label extension (OLE) Study to evaluate the long-term safety and efficacy of ABT-494 in subjects with ulcerative colitis (UC)	Innere Medizin III_716	Trauner Michael
FA716E0901	Doppelblinde, randomisierte, placebokontrollierte Phase III Studie zum Vergleich von Nor-Ursodeoxycholsäure Kapseln versus Placebo bei der Behandlung von primär sklerosierender Cholangitis	Innere Medizin III_716	Trauner Michael
FA716E0931	Eine randomisierte, doppelblinde Phase-3-Studie des Adjuvans Nivolumab gegenüber Placebo bei Teilnehmern mit hepatozellulärem Karzinom, die nach einer kurativen hepatischen Resektion oder Ablation ein hohes Rezidivrisiko aufweisen	Innere Medizin III_716	Trauner Michael
FA716E0951	Doppelblinde, randomisierte, Placebo-kontrollierte Phase-IIb-Studie zur Wirksamkeit und Sicherheit von Nor-Ursodeoxycholsäure-Tabletten bei Patienten mit nichtalkoholischer Steatohepatitis (NASH) und koordinierender Prüfarzt	Innere Medizin III_716	Trauner Michael

FA716E0968	WO41535 - A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Innere Medizin III_716	Trauner Michael
FA716E0974	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma	Innere Medizin III_716	Trauner Michael
FA716E1001	A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease	Innere Medizin III_716	Trauner Michael
FA716E1003	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease	Innere Medizin III_716	Trauner Michael
FA716E1012	A phase IIb, double-blind, randomised, placebo-controlled, trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet	Innere Medizin III_716	Trauner Michael
FA716E1013	A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis"	Innere Medizin III_716	Trauner Michael
FA716E1060	A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of	Innere Medizin III_716	Trauner Michael

	MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis		
FA716E1061	Cirrhotic cardiomyopathy: Analysis of pathomechanism involved in cardiac dysfunction during liver disease progression, regression and acute on chronic liver failure in two distinct murine models of cirrhosis	Innere Medizin III_716	Trauner Michael
FA716E1062	A Phase 2s multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with moderate to severe crohns disease	Innere Medizin III_716	Trauner Michael
FA716E1063	A multicenter, randomized study to evaluate the safety and efficacy of Lutikizumab for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E1064	A Phase Ib/II, open label multicenter, randomized platform study evaluating the efficacy and safety of neoadjuvant immunotherapy combinations in patients with surgically resectable hepatocellular carcinoma (Morpheus NEO HCC)	Innere Medizin III_716	Trauner Michael
FA716E1065	A Multicenter, Randomized, Double-blind, 2-Part Phase 2 Study to Evaluate the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) Part 1: Placebo-Controlled, Dose-Ranging Study of GS-1427; Part 2: Active-Controlled, Combination Study Evaluating the Efficacy and Safety of GS-1427 in Combination With Ustekinumab versus GS-1427 or Ustekinumab monotherapy	Innere Medizin III_716	Trauner Michael

FA716E1066	GA45329 - A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS	Innere Medizin III_716	Trauner Michael
FA716E1067	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn's Disease	Innere Medizin III_716	Trauner Michael
FA716E1069	Creating possibilities in HBV/HDV coinfection: improving care for viral hepatitis in vulnerable Viennese patient cohorts Creating Possible Award	Innere Medizin III_716	Trauner Michael
FW716B0101	Metabolische Kontrolle von Altern und Krankheit (MetAGE)	Innere Medizin III_716	Scherer Thomas
FW716B0201	CAH-X: Congenital adrenal hyperplasia with EDS.	Innere Medizin III_716	Scherthaner-Reiter Marie Helene
UE71606012	Qualitätszertifikat Vorsorgekoloskopie	Innere Medizin III_716	Trauner Michael
UE71606013	Ludwig Boltzmann Institut für Arthritis und Rehabilitation	Innere Medizin III_716	Bonelli Michael
FA781B1402	Jeffrey Modell Immunodeficiency Center @ MedUni Vienna	Kinder- und Jugendheilkunde_781	Förster-Waldl Elisabeth
FA781B1908	Retrospektive Datenanalyse von Kindern und Jugendlichen unter Fycompa Therapie bezüglich Therapiedauer, Effektivität und Safety Daten	Kinder- und Jugendheilkunde_781	Feucht Martha
FA781B1909	Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)	Kinder- und Jugendheilkunde_781	Feucht Martha

FA781B1910	EASEE4YOU – Eine klinische Prüfung der Sicherheit und Wirksamkeit der transkraniellen Kortextstimulation mit dem EASEE® System zur Behandlung medikamentenrefraktärer fokaler Epilepsie bei jugendlichen Patienten im Alter von 12 bis 17 Jahren	Kinder- und Jugendheilkunde_781	Feucht Martha
FA781B2503	EU Network of Youth Cancer Survivors	Kinder- und Jugendheilkunde_781	Leiss Ulrike
FA781B2605	A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)	Kinder- und Jugendheilkunde_781	Binder Christoph
FA781B2707	Adaptive simulation based on real time cognitive load, affective and biometric measures: virtual reality serious game application in realistic paediatric emergency skill training environment (VR-PMes)	Kinder- und Jugendheilkunde_781	Wagner Michael
FA781B2709	Training Health Professional Educators to teach interprofessional teams using simulation based immersive training	Kinder- und Jugendheilkunde_781	Wagner Michael
FA781B3209	Scanning the liquids of paediatric brain tumour patients to personalize treatment	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3505	EPILEPSY-RARE Vienna - Seltene EPILEPSIen bei Kindern und Jugendlichen - Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicheR Epilepsiesyndrome an der Medizinischen Universität Wien	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781B3505	EPILEPSY-RARE Vienna - Seltene EPILEPSIen bei Kindern und Jugendlichen - Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicheR	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia

	Epilepsiesyndrome an der Medizinischen Universität Wien		
FA781B3601	ReConNect: RemoteConsulting4NeonatalResuscitation - eine simulationsbasierte Pilotstudie	Kinder- und Jugendheilkunde_781	Rittenschober-Böhm Judith
FA781F0209	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-group, Outpatient Stuy Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate to Severe Atopic Dermatitis	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0210	Early allergen-specific immunotherapy to prevent the development of allergy	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0211	Wirksamkeit und Sicherheit der sublingualen SQ-tree-Immuntherapie-Tablette bei Kindern und Jugendlichen (im Alter zwischen 5 und 17 Jahren) mit mäßiger bis schwerer durch Birkenpollen und Pollen der Birkenhomologen Gruppe ausgelöster allergischer Rhinitis und/oder Konjunktivitis	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0215	A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (START UP)	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0603	A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome (Mucopolysaccharidosis II)	Kinder- und Jugendheilkunde_781	Konstantopoulou Vassiliki
FA781F0607	Optimization of management and quality of life of patients with lysosomal storage disorders	Kinder- und Jugendheilkunde_781	Konstantopoulou Vassiliki

FA781F0905	Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)	Kinder- und Jugendheilkunde_781	Rami-Merhar Birgit
FA781F1015	Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19)	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1016	Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (6 to less than 12 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-20)	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1205	Rare disease, more rare diagnosis: Mapping the accuracy of laboratory screening for rare bone disorders in Austria	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1206	XLH	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F2201	Writing Grant for Pediatric HoFH research with evinacumab	Kinder- und Jugendheilkunde_781	Nigmann Charlotte
FA781G0205	MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)	Kinder- und Jugendheilkunde_781	Huber Wolf-Dietrich
FA781G0207	Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn's Disease	Kinder- und Jugendheilkunde_781	Huber Wolf-Dietrich
FA781G0208	A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease	Kinder- und Jugendheilkunde_781	Huber Wolf-Dietrich

FA781G0405	ERKReg (The European Rare Kidney Disease Registry)	Kinder- und Jugendheilkunde_781	Arbeiter Klaus
FA781G1001	StOP Hypertension: imprOving Children's Lives after KidnEy TranSplantation	Kinder- und Jugendheilkunde_781	Memaran Dadgar Nima
FW781B0202	Plasticizer Exposure and its Consequence on health (PEACH)	Kinder- und Jugendheilkunde_781	Wisgrill Lukas
UE78106014	EOPD - Mobiler Psychologischer Dienst	Kinder- und Jugendheilkunde_781	Leiss Ulrike
UE78106015	NF Forscherwerkstatt	Kinder- und Jugendheilkunde_781	Pletschko Thomas
UE78106025	Vienna Preterm Neonates (ViP-Neo) Biobank	Kinder- und Jugendheilkunde_781	Wisgrill Lukas
FA765A0803	Home Treatment	Kinder- und Jugendpsychiatrie_765	Plener Paul
UE76506005	Forensik-Projekt	Kinder- und Jugendpsychiatrie_765	Plener Paul
FA729A0158	A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (disease caused by infection with severe acute respiratory syndrome coronavirus-2)	Klinische Pharmakologie_729	Jilma Bernd
FA729A0164	Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults	Klinische Pharmakologie_729	Jilma Bernd
FA729A0171	Single ascending dose study to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of SR-878 in healthy volunteers	Klinische Pharmakologie_729	Jilma Bernd
FA729A0172	CADALYST	Klinische Pharmakologie_729	Jilma Bernd
FA729A0173	A first-in-human phase I, open-label, dose-escalating trial to assess the safety, tolerability and immunogenicity / preliminary antitumor activity of ES2B-C001	Klinische Pharmakologie_729	Jilma Bernd

	with or without Montanide in HER2 expressing breast cancer.		
FA729A0174	PHASE IB OPEN LABEL BASKET STUDY OF RAY121 TO INHIBIT COMPLEMENT CLASSICAL PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL)	Klinische Pharmakologie_729	Jilma Bernd
FA729A0741	Comparison of the performance and safety of T2769 versus Vismed Multi in the treatment of moderate to severe Dry Eye Syndrome	Klinische Pharmakologie_729	Garhöfer Gerhard
FA729A1057	Progress new assets (one pre-new molecular entity and one first-time-inhuman start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB)	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1102	Defibrotide and Major Histocompatibility Complexes	Klinische Pharmakologie_729	Schörgenhofer Christian
FA729A1103	Effekte einer von Apothekern durchgeführten Medikationsanalyse auf Therapieadhärenz und andere Patienten-berichtete Parameter – eine randomisierte, kontrollierte, Patienten- und Beobachter-verblindete Studie in Patienten mit Polymedikation in Apotheken	Klinische Pharmakologie_729	Schörgenhofer Christian
FA729A1104	Effects of VGA039, a monoclonal protein S antibody, on ex vivo blood coagulation of healthy volunteers and of adult and pediatric patients with hemophilia A, hemophilia B and von Willebrand's disease	Klinische Pharmakologie_729	Schörgenhofer Christian
FA729A1312	Anti-inflammatory effects and clinical efficacy of topical Thealoz Total eye drops in patients with chronic dry eye disease and associated ocular surface inflammation	Klinische Pharmakologie_729	Schmidl-Schordje Doreen

FA729A1804	Comparative analysis of the in vitro PK/PD properties of Tonabacase and Exabacase	Klinische Pharmakologie_729	Nussbaumer-Pröll Alina
FA729A2202	Breadth and magnitude of immunological responses following JN.1 formulation of 2024/25 season COVID-19 mRNA vaccine in Europe and the United States	Klinische Pharmakologie_729	Pracher Lena Maria
FA729A2401	Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning (SNF)	Klinische Pharmakologie_729	Scholl Hendrik
FA712A0307	Personalized Drug Screening for Hematological Malignancies: 3D human bone marrow models with patient-derived cells	Krebsforschung_712	Berger Walter
FA712A0512	COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE	Krebsforschung_712	Sibilia Maria
FA712A1103	Forschungsgruppe	Krebsforschung_712	Heffeter Petra
FA712A1501	International PhD program in Translational Oncology	Krebsforschung_712	Szakacs Gergely
FA712A1502	Dynamical Systems and Reaction Kinetics Networks	Krebsforschung_712	Szakacs Gergely
FA712A1801	Innate immune reprogramming to overcome therapy resistance in high-risk colorectal cancer	Krebsforschung_712	Herndler-Brandstetter Dietmar
FA712A2005	Antibody repertoires against microbiota as biomarkers for ME/CFS	Krebsforschung_712	Vogl Thomas
FA712A2006	Deciphering systemic and mucosal antibody repertoires against the microbiota in ME/CFS and PCC	Krebsforschung_712	Vogl Thomas
FW712A0501	ILEI from the adrenal gland as first-aid after heart attack?	Krebsforschung_712	Csiszar Agnes
FA793A0338	TAK-577, Analytical Reports	Labormedizin_793	Quehenberger Peter
FA793A0339	rVWF Pediatric Prophylaxis Study	Labormedizin_793	Quehenberger Peter
FA793A1905	Alpha-1 sample analysis	Labormedizin_793	Haslacher Helmuth
FA793A1907	Blutausstriche und Knochenmark-Ausstriche Analyse: Leistungsbewertung Vision Pro	Labormedizin_793	Haslacher Helmuth
FA793A1908	The role of microalbuminuria in (Pre)diabetes in the Austrian General Population	Labormedizin_793	Haslacher Helmuth

FA793A2702	Fc engager in immune organoids	Labormedizin_793	Schmetterer Klaus
FA793A2802	Swedish Research Council	Labormedizin_793	Penninger Josef
FA793A2802	Swedish Research Council	Labormedizin_793	Penninger Josef
FA793B0124	Sammlung und Analyse von Daten antifungaler Resistenzen von Hefepilzen aus klinisch relevantem Untersuchungsmaterial für die Berichtsjahre 2024-2027	Labormedizin_793	Willinger Birgit
FA793C0205	A mono-center, retrospective clinical study with residual archived samples to evaluate the performance of the NeuMoDx™ HIV-1 Quant Assay on the NeuMoDx systems (for IVDR)	Labormedizin_793	Straßl Robert Paul
FW793A0101	Sialoproteome driven immune response in breast cancer	Labormedizin_793	Mereiter Stefan
FW793A0301	The role of protein sulfation in CD8+ T cells	Labormedizin_793	Schmetterer Klaus
FW793A0401	Meta-Entzündung in Psoriasis-assoziiierter Atherosklerose	Labormedizin_793	Mieczkowski Kamil
FA618A0703	OSAF US Grant DBA	Max Perutz Labs_305	Martinez Javier Augusto
FA631A0601	A unifying dynamical theory of distributed computation and generalisation in biological and artificial neural systems	Medical Data Science_303	Gosztolai Adam
FA660A1208	Datengetriebene Modellierung der Veränderung von Patientenströmen in der niedergelassenen Versorgung	Medical Data Science_303	Klimek Peter
UE60206002	Präzisionsmedizin bei Arthrose: Nutzung von KI für patientenindividuelle Vorhersagen, Monitoring und Behandlungsansätzen	Medical Data Science_303	Ritschl Valentin
UE63106001	CDG-Internships im CD-Labor für Künstliche Intelligenz in der Netzhaut 2024	Medical Data Science_303	Bogunovic Hrvoje
UE63106001	CDG-Internships im CD-Labor für Künstliche Intelligenz in der Netzhaut 2024	Medical Data Science_303	Bogunovic Hrvoje
CD10260504	Schalllabor für die Entwicklung der nächsten Generation von Ultraschallgeräten	Medizinische Physik und Biomedizinische Technik_340	Figl Michael

CD10260504	Schalllabor für die Entwicklung der nächsten Generation von Ultraschallgeräten	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A0212	Funktionelle MRT	Medizinische Physik und Biomedizinische Technik_340	Windischberger Christian
FA605A0413	Hybrid endoscope for esophageal in vivo histology and histochemistry	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
FA605A0705	Research-Neural-Interfaces Multikontaktelektrode für präklinische Versuche zur Verifizierung der Langezeitstabilität der Multikontaktelektrode	Medizinische Physik und Biomedizinische Technik_340	Lanmüller Hermann
FA605A1006	Hochauflösender Biosignalverstärker	Medizinische Physik und Biomedizinische Technik_340	Bijak Manfred
FA605A1603	Dynamic whole-body positron emission tomography for assessing inter-organ signaling	Medizinische Physik und Biomedizinische Technik_340	Beyer Thomas
FA605A1805	Photonics for Healthcare: multiscale cancer diagnosis and Therapy	Medizinische Physik und Biomedizinische Technik_340	Leitgeb Rainer
FA605A1807	Eurostars-3 CoD 1: 16 DOCTA - Development of digital OCT aberrometry system	Medizinische Physik und Biomedizinische Technik_340	Leitgeb Rainer
FA605A1908	New patient-specific surgical simulator	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A2603	Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacoustic tomography	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
FA605A3004	EU COST Action Radionuclide theragnostics for personalised medicine	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA605A3202	Novel Methods for Ultra-low Dose CBCT in Angiography	Medizinische Physik und Biomedizinische Technik_340	Birkfellner Wolfgang
FA605A3801	Human Factors Engineering of the Impella BTR Mobile Console: Eye-Tracking supported Simulated Use-Testing	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A3901	An Integrated Remote Cardiac Assist Device Patient Monitoring Platform	Medizinische Physik und Biomedizinische Technik_340	Haberbusch Max

FA605A4001	Total Optical Coherence Characterization for Automated Tumor Analysis	Medizinische Physik und Biomedizinische Technik_340	Merkle Conrad
FW605A0101	High-resolution imaging of the human claustrum	Medizinische Physik und Biomedizinische Technik_340	Windischberger Christian
UE60506007	Future SS-OCT technologies, High speed OCT, functional OCT and Synthetic aperture imaging OCT	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
UE60506007	Future SS-OCT technologies, High speed OCT, functional OCT and Synthetic aperture imaging OCT	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
UE60506007	Future SS-OCT technologies, High speed OCT, functional OCT and Synthetic aperture imaging OCT	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
FA660A1104	Statistische Beratung und Feedback bei Studien zu den Themen Digital Health, Big Data und Patientensicherheit - LBI-DHPS	Medizinische Statistik, Informatik und Intelligente Systeme_303	Heinze Georg
FA660A1105	Neuentwicklung eines Cardiac-Allocation-Scores (CAS)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Heinze Georg
UE63206001	Verein ASDI - Zertifizierung von Intensivstationen	Medizinische Statistik, Informatik und Intelligente Systeme_303	Graf Alexandra
FA736A0503	Hypericin-PVP in der photodynamischen Tumorthherapie: ein neues Behandlungskonzept für Glioblastoma mltiforme	Neurochirurgie_736	Widhalm Georg
FA736A0701	Iop. MRT Imaging	Neurochirurgie_736	Rössler Karl
FA736A0702	LITT - Therapie in der Neurochirurgie für Epilepsiechirurgie	Neurochirurgie_736	Rössler Karl
FW736A0101	Receptor-ligand synergies between medulloblastoma cell types	Neurochirurgie_736	Gabler Lisa
FA761A1123	1.) Serum Neurofilament light chains as a marker for neurological manifestation in Fabry Disease 2.) Neuroinflammation in Fabry Disease and Gaucher Disease: histopathological examination in human brains	Neurologie_761	Berger Thomas

FA761A1125	The effect of Cladribine on iron rims around lesions, lesion expansion, brain atrophy and disease progression in multiple sclerosis patients - an observational exploratory study	Neurologie_761	Berger Thomas
FA761A1170	A randomized, doubleblind, placebo.-controlled, multicenter phase 3 stStudy to evaluate the safety, tolerability and efficacy of XEN1101 as adjunctive therapy in focal-onset seizures	Neurologie_761	Berger Thomas
FA761A1171	A randomized study of XEN1101 versus placebo in primary generalized tonic-clonic seizures	Neurologie_761	Berger Thomas
FA761A1172	A phase 2/3 multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety and tolerability of BHV-7000 in subjects with refractory focal onset Epilepsy	Neurologie_761	Berger Thomas
FA761A1173	85000ML-45203, Risdiplam and Nusinersen in adults with 5q-associated spinal muscular atrophy: a multi-center observational health study	Neurologie_761	Berger Thomas
FA761A1174	A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension	Neurologie_761	Berger Thomas
FA761A1175	A Phase 2, Global Multicenter, Long-term Safety Study Designed to Assess teh Safety and Tolerability of BHV700 in Subjects with Refractory Focal Onset Epilepsy	Neurologie_761	Berger Thomas
FA761A1176	Assessment of the cellular cytotoxicity of IDP-023 in response to autoreactive B- and T cells Cells	Neurologie_761	Berger Thomas
FW761A0101	Molecular elucidation of loss-of function HACE1 mutations	Neurologie_761	Berger Thomas

FW796A0101	BraiNFC - a multisensory, digital journey through the brain	Neurologie_761	Amberg Nicole
UE76106005	NEW WAYS TO ASSESS TREATMENT RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS: COMBINED ASSESSMENT OF RETINAL THINNING, NEUROFILAMENTS AND OLFACTORY THRESHOLD (RNOT-SCORE) A PROSPECTIVE, OBSERVATIONAL STUDY	Neurologie_761	Berger Thomas
FA728A0607	Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study II	Notfallmedizin_728	Holzer Michael
FA728A1203	"Clinical Performance of Elecsys® Troponin T hs Gen 6 in Subjects with Symptoms of Acute Coronary Syndrome - PERFORM-TSIX Study - Study No. CIM RD005477"	Notfallmedizin_728	Niederdöckl Jan
FA728A1303	Digitalisierung medizinischen Wissens als Basis für intelligente Lösungen für die Hämato-Onkologie und Notfallmedizin	Notfallmedizin_728	Roth Dominik
FA728A1304	Prädiktion klima- und wetterbedingter Schwankungen in der Inanspruchnahme hospitaler Notfallstrukturen	Notfallmedizin_728	Roth Dominik
FA728A1501	Förderung weiterer Arbeit Forschungsgruppe Dr. Schnaubelt	Notfallmedizin_728	Schnaubelt Sebastian
FA737B0101	B1: Cartilage for Cartilage regeneration: Laser engraved decellularized cartilage as biomaterial for defect treatment	Orthopädie und Unfallchirurgie_739	Nürnberger Sylvia
FA681A0701	Genome of Europe	Pathobiochemie und Genetik_306	Hengstschläger Markus
FW608A0101	Oxidation-specific epitopes as regulators of MDSC in cancer	Pathobiochemie und Genetik_306	Oberle Raimund
FA791A0724	"GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES"	Pathologie_791	Müllauer Leonhard
FA791A1021	The purpose of the grant is to support the Banff Working Group for TMA in renal TX	Pathologie_791	Kozakowski Nicolas

FA791A1028	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Pathologie_791	Kain Renate
FA791A1038	“A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer”	Pathologie_791	Kain Renate
FA791A1039	the study entitled Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Patients with Previously Treated Advanced Melanoma (TEBE-AM)	Pathologie_791	Kain Renate
FA791A1040	A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression”	Pathologie_791	Kain Renate
FA791A1041	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)	Pathologie_791	Kain Renate
FA791A1042	A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy(CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or	Pathologie_791	Kain Renate

	borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)		
FA791A1043	A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy(CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)	Pathologie_791	Kain Renate
FA791A1044	Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE)	Pathologie_791	Kain Renate
FA791A1130	Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1138	A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)" ("Study") with protocol number JCAR017-FOL-001 ("Protocol");	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1144	An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases ATA129-EBV-205	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1148	A pivotal Phase II randomized, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in patients with relapsed/refractory	Pathologie_791	Simonitsch-Klupp Ingrid

	Diffuse Large B Cell Lymphoma (R-R DLBCL)		
FA791A1154	R-Pola-Glo - A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R CHOP	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1158	A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1159	A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2)	Pathologie_791	Simonitsch-Klupp Ingrid

FA791A1160	A PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH LENALIDOMIDE VERSUS RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY PARTICIPANTS WITH FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1161	A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1162	“A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF ODRONEXTAMAB (REGN1979) AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, AND CEMIPILIMAB (REGN2810), AN ANTIPROGRAMMED DEATH-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH BCELL MALIGNANCIES (CLIO-1)”	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1163	A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib	Pathologie_791	Simonitsch-Klupp Ingrid

FA791A1419	A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non Muscle Invasive Bladder Cancer Patients (POTOMAC) Zentrum Prof. Gust	Pathologie_791	Haitel Andrea
FA791A1427	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)	Pathologie_791	Haitel Andrea
FA791A1663	Phase II Study Of Trastuzumab-Deruxtecan (T-Dxd; DS-8201a) In HER2-Low Breast Cancer Patients Presenting With Newly Diagnosed Or Progressing Brain Metastases (The TUXEDO-4 Study).	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1664	A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1665	„RANDOMISIERTE, OFFENE STUDIE DER PHASE III ZUR BEWERTUNG DER WIRKSAMKEIT UND SICHERHEIT VON GIREDESTRANT IM VERGLEICH ZU FULVESTRANT, BEIDE IN KOMBINATION MIT EINEM CDK4/6-HEMMER, BEI ÖSTROGENREZEPTOR-POSITIVEM, HER2-NEGATIVEM FORTGESCHRITTENEM MAMMAKARZINOM MIT RESISTENZ GEGENÜBER EINER VORANGEGANGENEN	Pathologie_791	Bago-Horvath Zsuzsanna

	ADJUVANTEN ENDOKRINEN THERAPIE“		
FA791A1666	“A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)”	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1667	A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physicians choice chemotherapy compared to trastuzumab in combination with physicians choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1712	A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer” the “Study”), bearing protocol number FGCL-3019-087	Pathologie_791	Kain Renate

FA791A2114	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)	Pathologie_791	Pammer Johannes
FA791A2115	A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects with PD-L1 Positive Recurrent or Metastatic Head and neck Squamous Cell Carcinoma	Pathologie_791	Pammer Johannes
FA791A2116	A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) with HER2-activating mutations.	Pathologie_791	Pammer Johannes
FA791A2805	An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients with Hemophilia B	Pathologie_791	Schiefer Ana-Iris
FA791A3406	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer“ - interner Studiencode CAAA617B12302	Pathologie_791	Comperat Eva Maria

FA791A3417	"A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer"	Pathologie_791	Comperat Eva Maria
FA791A3418	A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations, Protocol: 42756493BLC3004 (MoonRise-1)	Pathologie_791	Comperat Eva Maria
FA791A3419	Studie metachroner isolierter Pankreasmetastasen nach Behandlung eines klarzelligen Nierenzellkarzinoms	Pathologie_791	Comperat Eva Maria
FA791A3602	"Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)"	Pathologie_791	Kain Renate
FA791A3901	A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients.	Pathologie_791	Kozakowski Nicolas
FA791A4001	1300Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma	Pathologie_791	Scharrer Anke

FA791A4101	A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CARCINOMA (MORPHEUS-NEO HCC)	Pathologie_791	Mozayani Behrang
FA791A4102	Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction/gastric cancer	Pathologie_791	Mozayani Behrang
FA623A0228	Influence of obesity on allergic asthma and vaccine response	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A1001	A phase 2b, controlled, open-label study to evaluate the humoral and cellular immune response and safety following two doses of an adjuvanted RSV subunit vaccine in immunocompromised adults	Pathophysiologie, Infektiologie und Immunologie_370	Wagner Angelika
FA624A0219	Profiling the binding specificities of fully human polyclonal ATG from Transchromosomic Bovines™ to T cell surface proteins	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0304	KOOPERATIONSVERTRAG EZ4U	Pathophysiologie, Infektiologie und Immunologie_370	Ellmeier Wilfried
FA624A0404	Approaches for treatment and prevention of asthma and anaphylaxis in an allergen-specific humanized mouse model	Pathophysiologie, Infektiologie und Immunologie_370	Pickl Winfried
FA644A0205	Bestimmung der Reinigungs- und Desinfektionswirkung im Praxistest - Hagleitner Hygiene International GmbH	Pathophysiologie, Infektiologie und Immunologie_370	Suchomel Miranda
FA644A0205	Bestimmung der Reinigungs- und Desinfektionswirkung im Praxistest - Hagleitner Hygiene International GmbH	Pathophysiologie, Infektiologie und Immunologie_370	Suchomel Miranda

FA644A0206	Bestimmung der Reinigungs- und Desinfektionswirkung im Praxistest - Hollu Systemhygiene GmbH	Pathophysiologie, Infektiologie und Immunologie_370	Suchomel Miranda
FA644A0207	Prüfung von Mundspüllösungen in Interaktion mit Zahnpasten in quantitativen Suspensionsversuchen nach EN 13727	Pathophysiologie, Infektiologie und Immunologie_370	Suchomel Miranda
FA644A0407	FUTURE DANUBE – Predicting future trends in health-related microbiological water quality of rivers in a vastly changing world	Pathophysiologie, Infektiologie und Immunologie_370	Sommer Regina
FA644A0510	Mikrobiologische und chemo-physikalische Echtzeitparameter zur Qualitätskontrolle in der mobilen Trinkwasseraufbereitung	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA644A0801	Immunometabolic analyses of transmissible cancer	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
FA644A0804	Pioneering a Transdisciplinary Urban Surveillance System for Human Papilloma Virus with Vulnerable Communities	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
FA644A1101	Joint central European Actions for Improving Quality of Urban Bathing Waters	Pathophysiologie, Infektiologie und Immunologie_370	Reiter Michael
FA648A0317	Development of allergen microarray silicon chips	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0319	Towards molecular allergen-specific treatment and prevention of peanut allergy	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0618	Unterstützung der Errichtung und Betreuung eines Editorial Office für die Wiener Medizinische Wochenschrift und der Publikationstätigkeit der Arbeitsgruppe für Knochenforschung	Pathophysiologie, Infektiologie und Immunologie_370	Pietschmann Peter
FA648A0810	Advanced molecular diagnosis of tree nut allergies	Pathophysiologie, Infektiologie und Immunologie_370	Breiteneder Heimo
FA648A1714	Allergenicity testing of allergen-immunotherapy (AIT) candidates for treatment of peanut allergy in a murine peanut allergy model	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva

FA648A1715	Analyse der Wirkungsweise einer intravenösen Laserbestrahlung zur Behandlung des Post-COVID Fatigue Syndroms	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1716	The impact of mast cell activation on epithelial and endothelial barrier dysregulation in post-infectious ME/CFS	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1904	DARC 2.0 Teilprojekt03: Towards cure and prevention of birch pollen-related food allergy	Pathophysiologie, Infektiologie und Immunologie_370	Bohle Barbara
FA648A2102	Towards safe molecular vaccines for allergy to Blomia tropicalis and tropomyosin-induced anaphylaxis	Pathophysiologie, Infektiologie und Immunologie_370	Vrtala Susanne
FA648A2501	Towards personalized treatment of allergen- and virus-induced asthma	Pathophysiologie, Infektiologie und Immunologie_370	Niespodziana Katarzyna
FA648A2601	Towards safe forms of molecular immunotherapy for venom allergy	Pathophysiologie, Infektiologie und Immunologie_370	Gattinger Pia
FW623A0101	Multi-omics to probe Acanthamoeba extracellular vesicles	Pathophysiologie, Infektiologie und Immunologie_370	Loufouma Mbouaka Alvie Chinoston
FW623A0201	Mapping the Signaling Network of Muscle-Specific Kinase	Pathophysiologie, Infektiologie und Immunologie_370	Herbst Ruth
FW623A0202	Interactome mapping of Rin-like signaling in T cells	Pathophysiologie, Infektiologie und Immunologie_370	Herbst Ruth
FW623A0301	Uncovering Vaccine Immune Response Dynamics in Obesity	Pathophysiologie, Infektiologie und Immunologie_370	Inic-Kanada Aleksandra
FW623A0302	Unveiling a local immune response in chlamydial infection	Pathophysiologie, Infektiologie und Immunologie_370	Inic-Kanada Aleksandra
FW623A0401	Antioxidant proteins and metronidazole in Giardia lamblia	Pathophysiologie, Infektiologie und Immunologie_370	Leitsch David
FW648A0201	Epitope recognition patterns in grass pollen allergy	Pathophysiologie, Infektiologie und Immunologie_370	Radauer Christian
FA726A0701	Evaluierung BVAEB-Gesundenuntersuchung Gesundheit und Beruf (GuB)	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726	Steiner Margarete
CD10262501	CD-Labor für Argininmetabolismus in Rheumatoider Arthritis und Multipler Sklerosis	Physiologie und Pharmakologie_350	Schabbauer Gernot

FA625A0906	Design Validation Study Protocol - Comparison of Platelet-rich Plasma (PRP) prepared using different design of PRP device and Centrifuges	Physiologie und Pharmakologie_350	Assinger Alice
FA625A1107	INV501 compounds and other discovery compounds in anti-cancer immunity	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA625A1301	Promoting RObust Systems biology on Patients and Experimental models with obesity-driven liver cancer	Physiologie und Pharmakologie_350	Sharif Omar
FA641A1302	Discovery and Characterization of peptides from African plants	Physiologie und Pharmakologie_350	Hellinger Roland
FA641A1501	Pharmakologische Stimulation von Blutstammzellen mit Fokus auf den Calcium-sensing Rezeptor	Physiologie und Pharmakologie_350	Zebedin-Brandl Eva Maria
FW641A0501	The Exocyst complex in dopamine transporter trafficking	Physiologie und Pharmakologie_350	Kasture Ameya
FA731F0507	Natural Integration of Bionic Limbs via Spinal Interfacing	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Aszmann Oskar
FA734A0101	Erhöhung der Adhärenz von Spalthauttransplantaten über Gelenken durch Reduktion von Reibung und Scherkräften via Lokaltheraeutika	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Supper Paul
FA763B1201	Eine randomisierte, doppelblinde, placebokontrollierte Phase III Studie zur Untersuchung der Wirksamkeit und Sicherheit von BI 425809 bei einer einmal täglichen Gabe über einen Behandlungszeitraum von 26 Wochen bei Patienten mit Schizophrenie (CONNEX-3)	Psychiatrie und Psychotherapie_763	Rujescu-Balcu Dan
FA763B1202	1346-0014 Eine unverblindete Verlängerungsstudie mit einem Behandlungsarm zur Untersuchung der langfristigen Sicherheit von Iclepertin einmal täglich bei Patienten mit Schizophrenie, die eine vorausgehende Studie der Phase III mit Iclepertin abgeschlossen haben	Psychiatrie und Psychotherapie_763	Rujescu-Balcu Dan

FA763B1401	Die Vielfalt des Gehirns	Psychiatrie und Psychotherapie_763	Spurny-Dworak Benjamin
UE76606001	Emergent Patterns of clinical Psychoanalytic Development: A Mixed Method approach for Education an Progression Commitees search: PCC Q-Sort and single Case Study Methodology	Psychoanalyse und Psychotherapie_766	Löffler-Stastka Henriette
FA636A0409	Adult patients with severe and very severe ME/CFS in Austria. A multi-perspective study.	Public Health_380	Hoffmann Kathryn
FA638A0405	Austrian Cohort Initiative	Public Health_380	Schernhammer Eva
FA646A0305	Social Sciences Participatory Research-Action for Preparedness in Risk Management for Disasters and Health Emergencies in Europe's Cities	Public Health_380	Kutalek Ruth
FA646A0706	Digitale Gesundheitsförderung: Studie zur Qualitätssicherung von digitalen Gesundheitsinformationen	Public Health_380	Grabovac Igor
FA646A0707	Co-Captain Vienna: Psychiatric disorders as a cancer co-morbidity	Public Health_380	Grabovac Igor
FA646A1201	ACE Casino	Public Health_380	Fischer Gabriele
FA646A1202	ASW Wetten	Public Health_380	Fischer Gabriele
FA646A1601	Study on Notice and Action Mechanisms	Public Health_380	Naderer Brigitte
FA647A0118	EU Knowledge for improving indoor AIR quality and HEALTH	Public Health_380	Moshhammer Hanns
FA669A0112	Establishing a Reference Unit Cost catalogue for the optimized evaluation and planning of mental healthcare in Vienna	Public Health_380	Simon Judit
FW646A0101	Parental Media Intervention for Resilience in LGBTQ+ Youth	Public Health_380	Niederkrotenthaler Thomas
FA771B0427	Durchführung einer klinischen Prüfung gemäß Medizinproduktegesetz/MDR auf dem Gebiet der kontrastverstärkende Röntgendiagnostik.	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B1308	Content-Based Retrival System	Radiologie und Nuklearmedizin_771	Prosch Helmut

FA771B1901	A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVD) in Participants with Relapsed or Refractory Myeloma who Have Received 1-4 Prior Lines of Therapy Including an AntiCD38 Antibody and Lenalidomide	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B1902	Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B1903	A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771D0533	Characterization of Mid-term Post Market Clinical Follow Up of GORE®TAG®Thoracic Branch Endoprosthesis Facilitated Aortic Arch and Descending Aorta Intervention	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0534	"Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction/gastric cancer"	Radiologie und Nuklearmedizin_771	Wolf Florian

FA771D0535	"A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression"	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771E0511	Projekt KI in der Radiologie um nutzerorientierte Strategie für den Zukünftigen Einsatz von künstlicher Intelligenz in den praktischen Arbeitsabläufe.	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E1603	ONCE201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy, a randomized, Double-Blind, Placebo-Controlled, Multicenter Study	Radiologie und Nuklearmedizin_771	Kasprian Gregor
FA771G0225	Identifizierung von ED-B Fibronectin an Gewebeproben (Onkologie und Kardiovaskular) durch immunhistologische Aufarbeitung mit ED-B Affilin.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0273	Preclinical molar ratio study to mitigate [90Y]Y-PentixaTher-mediated myelosuppression.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0273	Preclinical molar ratio study to mitigate [90Y]Y-PentixaTher-mediated myelosuppression.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0283	Purpose of using data and results for the purpose of applying by ITM or its Affiliates for regulatory approval and internal research by ITM in relation to the use of/treatment with Ac-ibuDAB-PSMA in patients	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0284	F18-ATD001 using non-radioactive precursors (ATD001p and a second precursor, PNEB). MTA	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0285	Application and further evaluation of RayzeBio compounds	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0286	Orano	Radiologie und Nuklearmedizin_771	Hacker Marcus

FA771ZZZZZ	“Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreak 301)”	Radiologie und Nuklearmedizin_771	Wolf Florian
FW771E0201	Förderung von thematisch klar abgegrenzten Forschungsvorhaben internationalem Niveau im Bereich der Grundlagenforschung. UTE in Osteoarthritis	Radiologie und Nuklearmedizin_771	Juras Vladimir
FA774A0204	“Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial” (“Studie”)	Radioonkologie_774	Kauer-Dorner Daniela
FA774A0503	Korrelation von Oberflächendaten mit X-Ray Daten (Phantombehandlung)	Radioonkologie_774	Lechner Wolfgang
FA774A0505	MR-Visible Plastics in Radiation Oncology	Radioonkologie_774	Lechner Wolfgang
FW774A0101	FWF Pre-clinical Ion Beam Research - DFH 13-B	Radioonkologie_774	Georg Dietmar
FW774A0201	Genome Instability	Radioonkologie_774	Slade Dea
FW774A0301	Dosimetrie in Magnetfeldern für MR-geführte Ionentherapie	Radioonkologie_774	Fuchs Hermann
FW774A0401	Antrag zu Autonome Bestrahlungsplanung in der Strahlentherapie	Radioonkologie_774	Heilemann Gerd
FA731T0202	APOSEC to clinic	Thoraxchirurgie_733	Ankersmit Hendrik
FA731T0504	A Phase III Prospective Multicenter Randomized Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow Device plus Standard of Care versus Standard of Care Alone in the Treatment of Bronchiolitis	Thoraxchirurgie_733	Jaksch Peter

	Obliterans Syndrome in Patients post Double Lung Transplantation		
FA731T0506	Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial	Thoraxchirurgie_733	Jaksch Peter
FA733A0301	A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis	Thoraxchirurgie_733	Jaksch Peter
FW733A0101	The use of extracorporeal photopheresis as immunomodulatory therapy of subclinical antibody-mediated rejection after lung transplantation: a prospective RCT	Thoraxchirurgie_733	Benazzo Alberto
FA727A0618	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FA727A0621	Agreement for Medical Writing Support: Extracorporeal photopheresis in Chronic graft versus host disease	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FW727A0101	Engineering of CD3 signaling chains for CAR T cell therapy	Transfusionsmedizin und Zelltherapie_727	Zajc Charlotte

FA670A0107	Surefil one als Amalgamersatz für Klasse II Füllungen im Studentenkurs	Universitätszahnklinik _670	Schedle Andreas
FA670A0109	Optimization of the handling of direct and indirect restorative materials and cements - development of an in-vitro test strategy	Universitätszahnklinik _670	Schedle Andreas
FA670A0110	Survival of bulk-fill resin restorations in posterior teeth within a 15-year period (2009-2024)	Universitätszahnklinik _670	Schedle Andreas
FA670B0103	FFG Praktikum	Universitätszahnklinik _670	Gruber Reinhard
FA670B0104	FFG Praktikum	Universitätszahnklinik _670	Gruber Reinhard
FA670B0105	FFG Praktikum	Universitätszahnklinik _670	Gruber Reinhard
FA670F0301	Initial adhesion and proliferation of gingival fibroblasts on dental implants	Universitätszahnklinik _670	Andrukhov Oleh
FA670F0502	TMJ SYMPHONY: Systems-integrated model and mechanisms of patient-centered holistic outcomes and network-supported training and therapy	Universitätszahnklinik _670	Sagl Benedikt
FA743A0106	"Projekttitel (Deutsch): REASSURE - Radium-223 alpha-Strahler in einer Sicherheitsstudie zur Langzeituntersuchung in mCRPC Patienten 1.1. Projekttitel (Englisch): REASSURE - Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation"	Urologie_743	Kramer Gero
FA743A0116	A Retrospective, Multicenter Study of Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Patients treated with Apalutamide Under Routine Clinical Practice (ArtemisR)	Urologie_743	Kramer Gero
FA743A0232	A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy	Urologie_743	Shariat Shahrokh

	with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer		
FA743A0233	Eine randomisierte, unverblindete, multizentrische, weltweit durchgeführte Studie der Phase III von Durvalumab und Bacillus Calmette-Guérin (BCG) verabreicht als Kombinationstherapie im Vergleich zu BCG alleine bei Patienten mit Hochrisiko nicht-muskelinvasivem Blasenkarzinom	Urologie_743	Shariat Shahrokh
FA743A0238	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer(mCRPC)	Urologie_743	Shariat Shahrokh
FA743A0242	Eine Phase-III-Studie zu BCG mit oder ohne Pembrolizumab für Hochrisiko-, nicht-muskelinvasiven Blasenkrebs (KEYNOTE-676)	Urologie_743	Shariat Shahrokh
FA743A0252	A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors	Urologie_743	Shariat Shahrokh
FA743A0254	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Urologie_743	Shariat Shahrokh
FA743A0261	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with	Urologie_743	Shariat Shahrokh

	Progressive Metastatic Castrate Resistant Prostate Cancer		
FA743A0262	PSMAAddition: An International Prospective Open-label, Randomized, Phase III Study comparing ¹⁷⁷ Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).	Urologie_743	Shariat Shahrokh
FA743A0276	A Phase 3 Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants with Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations	Urologie_743	Shariat Shahrokh
FA690A0503	Comparison of TTV PCR assays	Virologie_307	Puchhammer Elisabeth
FA690A0505	Testung von TTV DNA nach Nierentransplantation	Virologie_307	Puchhammer Elisabeth
FA690A0705	Epidemiological pattern of RSV circulation during and after SARS-CoV-2 pandemic, and analyses of the annual RSV epidemiology including viral co-infections	Virologie_307	Redlberger-Fritz Monika
FA690A1001	Collaborative Virus Research between Taiwan and Austria: Exploring Dengue virus Transmission Dynamics and Immune Responses	Virologie_307	Camp Jeremy Vann

Markus Müller

Rektor